Table 2. VLP entry inhibition results.

Conc, concentration tested in initial VLP-GP1,2 entry inhibition assay in SNB19 cells. Yes indicates inhibition of >90%.

Drug nameStructureConc (μM)Inhibit EBOV-VLP
entry
AripiprazoleAmphiphile10Yes
AstemizoleAmphiphile5Yes
AtovaquonePhenol0.8No
AzacitidineCarbohydrate10No
BenztropineCAD10Yes
BepridilCAD10Yes
ClemastineCAD4Yes
Clomiphene*CAD5Yes
ClomipramineCAD10Yes
DasatinibCAD10Yes
EfavirenzAnhydride10Yes
FlupentixolCAD10Yes
FluphenazineCAD10Yes
HycanthoneCAD10Yes
LomerizineAmphiphile10Yes
MaprotilineCAD10Yes
Mycophenolate mofetilAmphiphile1No
ParoxetineAmphiphile10Yes
PimozideAmphiphile10Yes
PiperacetazineAmphiphile10Yes
ProchlorperazineCAD10Yes
QuinacrineCAD10Undetermined
SertralineCAD10Yes
SimvastatinEster10Yes
StrophanthinCarbohydrate0.1No
TeicoplaninCAD10Yes
TerconazoleCAD12Yes
ThioridazineCAD10Yes
Toremifene*CAD0.8Yes
VinorelbineAmphiphile5Yes

*Entry inhibition activity also described by Johansen et al. (11).

†Quinacrine is an autofluorescent compound, and its ability to inhibit EBOV-VLP entry could not be assessed in this assay.

‡Entry inhibition also described by Shoemaker et al. (14).